Actively Recruiting
Application of Radiomics-based AI Models in Predicting Clinical Outcome of Patients With Renal Cell Carcinoma After Surgical Treatment (AI-Kidney-Prognosis)
Led by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Updated on 2025-08-12
400
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are conducting a prospective observational cohort study called AI-Kidney-Prognosis to use radiomics-based artificial intelligence models to predict clinical outcomes in patients with renal cell carcinoma following surgical treatment. The goal is to help guide clinical decisions and personalize follow-up care for these patients. The study involves analyzing imaging and clinical data from patients treated for renal cell carcinoma at Wuhan Union Hospital between August 2025 and August 2026. Participants must have had at least one abdominal CT scan before treatment and a confirmed diagnosis through tissue biopsy. No active treatments or interventions are administered as part of this observational study. Participants will be followed to monitor progression-free survival over one year after surgery. Researchers will collect and analyze imaging and clinical information to evaluate how well AI models can predict patient outcomes. The study includes regular data review and follow-up to support personalized patient care planning, with the total observation period extending for at least one year.
CONDITIONS
Brief Title
Application of Radiomics-based AI Models in Predicting Clinical Outcome of Patients With Renal Cell Carcinoma After Surgical Treatment
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients treated for renal cell carcinoma in Wuhan Union Hospital from August 2025 to August 2026
- Aged over 18 years old
- At least one abdominal CT scan before treatment
- Diagnosis of renal cell carcinoma confirmed by tissue biopsy pathological examination
You will not qualify if you...
- Poor image quality
- Incomplete clinical data or loss of follow-up
- Presence of another primary malignancy besides renal cell carcinoma
- Unclear pathological diagnosis
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 1 month
Participants undergo abdominal CT scans and tissue biopsy to confirm diagnosis of renal cell carcinoma.
1 to 2 visits depending on imaging and biopsy scheduling
Duration - Up to 1 year
Participants are followed to monitor progression-free survival after surgical treatment of renal cell carcinoma.
Periodic follow-up visits for up to 12 months
Trial Site Locations
Total: 1 location
1
Union Hospital，Tongji Medical College，Huazhong University of Science and Technology
Wuhan, Hubei, China, 430000
Actively Recruiting
Research Team
L
Lian Yang
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here